KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Leases: 2009-2025

Historic Capital Leases for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Sep 2025 value amounting to $720.0 million.

  • Regeneron Pharmaceuticals' Capital Leases changed negligibly% to $720.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $720.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $720.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Capital Leases of $720.0 million as of Q3 2025, which was down 0.00% from $720.0 million recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Capital Leases ranged from a high of $720.0 million in Q1 2022 and a low of $720.0 million during Q1 2022.
  • Its 3-year average for Capital Leases is $720.0 million, with a median of $720.0 million in 2025.